CSIMarket Company Name, Ticker, Industry, else..
Amicus Therapeutics inc   (NASDAQ: FOLD)
Other Ticker:  
 


 

Amicus Therapeutics inc

FOLD's Financial Statements and Analysis



Amicus Therapeutics inc reported in the third quarter of 2025 net earnings per share of $0.06 an improvement compare to net loss per share of $-0.02 recorded a year ago and an improvement compare to net loss per share of $-0.08 realized in previous quarter.


third quarter of 2025
Earnings Per Share Revenues
$ 0.06 $  169 Mill
$+0.08     $+27M     +19.37 %



Amicus Therapeutics Inc 's Revenue rose by 19.37 % in third quarter of 2025 (Sep 30 2025) year on year, to $169 million and advanced by 9.14 % sequentially.


Amicus Therapeutics Inc is

More on FOLD's Income Statement



Amicus Therapeutics Inc 's net income of $17.306 million in the third quarter of 2025 increased from net loss of $-6.729 million III. Quarter a year ago.

Sequentially Company turn into Profitability from net loss of $-24.420 million recorded in previous quarter.

More on FOLD's Growth

Amicus Therapeutics Inc Inventories
Inventories grew by 54.27 % to $178 million from III. Quarter a year ago, sequentially inventories rose by 14.88 %. FOLD's Cash flow In the third quarter of 2025 company's net cash flow was $32 million, capital expenditures fell by -0.3567.30%, to $0 millions compare to same quarter a year ago

More on FOLD's Cash flow Statement


Amicus Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Amicus Therapeutics inc earned $ 0.04 cash per share, on a free-cash flow basis .

Book value grew by 11.99 % sequentially to $0.74 per share.


Company issued 2.18 million shares or 0.71 % in Sep 30 2025.
Interest Coverage Ratio was 1.4. Debt Coverage Ratio was 0.04.

• More on FOLD's Dividends

 Market Capitalization (Millions) 2,943
 Shares Outstanding (Millions) 310
 Total Debt (Millions $) 392
 Revenue (TTM) (Millions $) 597
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -43
 Capital Exp. (TTM) (Millions $) -3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 1,246




Amicus Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Amicus Therapeutics inc had $ 0.04 cash flow per share, on a free-cash flow basis .

Book value grew by 11.99 % sequentially to $0.74 per share.


Company issued 2.18 million shares or 0.71 % in Sep 30 2025.
Interest Coverage Ratio was 1.4. Debt Coverage Ratio was 0.04.

• More on FOLD's Balance Sheets

 Market Capitalization (Millions) 2,943
 Shares Outstanding (Millions) 310
 Total Debt (Millions $) 392
 Revenue (TTM) (Millions $) 597
 Net Income (TTM) (Millions $) -14
 Cash Flow (TTM) (Millions $) -43
 Capital Exp. (TTM) (Millions $) -3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 1,246
   


  News about Amicus Therapeutics inc Earnings

Despite Revenue Boost, Amicus Therapeutics Inc Falls Short of Profitability Goals in Q1 2024



Amicus Therapeutics Inc, a major player in the pharmaceutical preparations industry, recently announced its financial results for the first quarter of 2024. While the company experienced a surge in revenue compared to the previous year, it also reported a net loss. Furthermore, the stock's performance in the market has been relatively volatile. This article will delve into the implications of these financial results and speculate on how they might affect Amicus Therapeutics Inc's future prospects.
Positive Revenue Growth:
One promising aspect of Amicus Therapeutics Inc's financial results is its revenue growth in Q1 2024. The company witnessed an impressive 27.317% increase in revenue, reac...

Amicus Therapeutics Inc Faces a Shortfall of $-0.11 per Share in Fourth Quarter of 2023

Amicus Therapeutics Inc, a major player in the pharmaceutical preparations industry, recently announced its financial results for the fourth quarter of 2023. Despite reporting a net loss of $-0.11 per share, the company's revenue experienced a significant surge of 31.466%, amounting to $115.82 million. This represents a remarkable 21% increase in total revenue compared to the previous year.
When compared to the preceding quarter, where the company generated $102.56 million in revenue and reported a net loss of $-0.07 per share, these figures demonstrate promising growth for Amicus Therapeutics Inc. Furthermore, the company's net shortfall decreased from $-55.865 million to $-33.843 million in the same fi...

Amicus Therapeutics Inc Faces Mounting Shortfall, Sending Shockwaves through the Pharmaceutical Industry in 2023 Q3

Amicus...

Amicus Therapeutics Inc Shows Resilience with Strong Overall Performance Despite Recent Share Decrease and Increased Losses

Amicus Therapeutics Inc, a pharmaceutical company, has experienced a slight decrease in its shares over the past five trading days. The shares went down by -0.26%, which brings the year-to-date performance to 13.75%. Despite this decrease, it is worth noting that the shares are only 2% short of the 52-week high, indicating a strong performance overall.
Looking at the company's financial performance, it can be observed that for the April to June 30, 2023 fiscal period, there was a significant increase in losses compared to the same period the previous year. The losses swelled to $-0.15 per share, whereas they were $0.00 per share a year before. However, there was an improvement in earnings per share from ...

Amicus Therapeutics Inc sees revenue growth, but widening deficit threatens first quarter of 2023 earnings

Investing in the stock market can be an exciting and rewarding experience. However, it is crucial to approach investment decisions with caution and careful consideration. This is especially true when it comes to investing in individual companies and stocks that are subject to fluctuations in performance, such as Amicus Therapeutics Inc.
According to recent financial reports released by Amicus Therapeutics Inc, the company's shortfall per share has expanded to $-0.18 from $0.00 year on year. This is a significant change in performance and should be of concern to investors looking to invest in the company. While revenue growth has increased by 9.598% to $86.27 million, the overall financial picture is not ...


Date modified: 2025-11-11T16:02:31+00:00




Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.